Furthermore, preclinical and clinical data indicate that 4-(1H-pyrazolo[3,4-b]pyridine-1-yl)benzamide TAS-116 (Pimitespib), a selective oral inhibitor of cytosolic Hsp90α and β, exhibits a potent anti-tumor activity in various cancers with minimal side effects, including visual disturbances20–23. Here, HSP90AA1 is linked to neoplasm.